Thank you for visiting, don't forget to subscribe by following here if you enjoy our content. We use follow.it to give you maximum control over your news.
The Sackler family and their pharmaceutical enterprise Purdue Pharma have reached a landmark £7.4 billion settlement over their involvement in the US opioid crisis, marking a significant development in one of healthcare’s most contentious legal battles.
The revised agreement, which surpasses the previous arrangement by £1.4 billion, awaits bankruptcy court approval and represents a collaborative effort between the company and multiple US states. Under the terms, the Sackler family will contribute £6.5 billion over 15 years, whilst Purdue Pharma will provide £900 million.
The settlement’s structure differs notably from its predecessor, which the Supreme Court rejected last summer. The new arrangement carefully navigates liability protections, requiring victims to waive future legal action in exchange for compensation – a crucial distinction from the earlier blanket immunity provisions.
Approximately 140,000 personal injury victims stand to benefit from this settlement, according to court documents. The funds will be allocated over 15 years to support opioid addiction treatment and recovery programmes, addressing a crisis that has claimed more than 600,000 lives since 1999.
A significant victory for advocates lies in the settlement’s operational restrictions – the Sackler family can no longer sell opioids in the US market, and their ownership of Purdue Pharma has ceased. This development arrives after Purdue’s 2020 guilty plea to federal felony charges, which included admissions of improper marketing practices and physician incentivisation.
The comprehensive details of the payout structure remain pending, with a 50-page term sheet expected to emerge in the coming weeks. This document will clarify crucial aspects of victim compensation and programme funding allocation, potentially setting a precedent for future mass tort resolutions in the pharmaceutical sector.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.